Nanjing innovative drug research adds new force. On March 25, the development center of innovative macromolecular drugs and the Innovation center of Antibody Coupling drugs were unveiled in Jiangning High-tech Zone, Nanjing.
With a number of innovative drugs in hand, Aoke Immunity has always been a hot spot in the industry and capital circles. In 2000, Dr. Liu Yang, Zheng Pan, Guan Kunliang, and You Ming, internationally renowned scientists and scientists, founded the United States Envision Immune, and in 2020, the international pharmaceutical giant acquired the company's new coronavirus treatment drug CD24Fc with a down payment of 425 million US dollars. With the rise of domestic innovative drug research and development, Aoke immunization has accelerated its layout in many places in China. In 2022, Aoke Immune set up a company in Nanjing, as China's R & D center and future industrialization base, committed to the development of innovative immunotherapy drugs, focusing on the immunotherapy of malignant tumors and inflammatory diseases, and bringing more treatment means to clinical patients.
Angke Immune in Jiangning high-tech Zone to build R & D and industrialization base project, the project will use a total of 6000 square meters of plant in Ruihong cell and gene industrial Park to build R & D center and pilot workshop, accelerate the development of innovative drug products and approval process. At present, the R & D laboratory, pilot workshop, quality control laboratory and other renovated, R & D personnel have been stationed and started the project experiment.
With a total investment of about 280 million yuan and a R&D staff of 70 people, the company is committed to the development of innovative immunotherapy drugs and strives to bring more of the best products of the same kind to clinical patients. Antibody coupling drug is a new type of cancer treatment drug, which belongs to the perfect combination of chemotherapy and immunotherapy, and has become a hot track in the layout of global pharmaceutical companies. "I chose Nanjing Jiangning because of the investment and talent environment here." Liu Yang, founder and chairman of the company, said that the Nanjing research and development center has three research and development projects into the clinical stage, and technology transfer and technical service revenue of more than 14 million US dollars. It is expected that with the launch of the product, the cumulative output value of five years is not less than 5 billion yuan, and the cumulative tax is not less than 450 million yuan.
At present, Jiangning High-tech Zone has gathered more than 300 biomedical enterprises, forming five industrial sectors of pharmaceutical research and development and production, cell therapy, research and development service outsourcing (CRO), testing and inspection, and high-end medical devices, forming a full life cycle innovation ecology covering registration and testing, product certification, technical improvement, and quality system.
The person in charge of Jiangning High-tech Zone said that the development of Aoke Immunity has been widely reported, and major breakthroughs have been made in the research and development of severe immune drugs and innovative drugs for a variety of solid tumors, and scientific and technological research, leading the industry reform of macromolecular drug innovation. The official opening of the two research centers not only marks the development of enterprises into the fast lane, but also marks the development of macromolecular innovative drug industry in Jiangning has entered a new stage.
Meeting point reporter Qiu Huidong, correspondent Jiang Gaoxuan
